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Abstract 
BACKGROUND: Ovarian tissue cryopreservation has the potential to improve 
fertility preservation for a growing number of patients undergoing sterilising therapy, 
particularly where oocyte or embryo cryopreservation is not suitable. However, its success is 
limited by significant follicular apoptosis upon thawing, and there is wide variation in 
thawing protocols used with little evidence of efficacy. OBJECTIVE: To determine the best 
warming rates to maintain tissue viability.  MATERIALS AND METHODS: Ovarian tissue 
biopsies from 11 patients were taken with informed consent and divided into four pieces, 
which were allocated to either fresh assessment or to one of several freeze-thaw protocols. 
Cryopreservation was undertaken using a Stirling cycle cryo-cooler and cryopreserved 
samples were exposed to different warming protocols. Tissue conservation was then assessed 
using a marker, neutral red, to identify viable follicles.  RESULTS: The results showed 
greatest follicle conservation rates in fresh samples, followed by those thawed using a rapid 
thawing protocol (Protocol 1). Tissue thawed using an ultra fast protocol (Protocol 2) and 
slow warming (Protocol 3) resulted in greater follicle loss.  CONCLUSION: These 
preliminary results indicate thawing conditions significantly affect follicle conservation in 
cryopreserved human ovarian tissue. 
Keywords: fertility preservation, cryopreservation, thawing protocols, human ovarian tissue, 
and follicle conservation 
 
INTRODUCTION 
According to the most recent data 
published by Cancer Research UK (2), 
374,400 new cases of cancer were diagnosed 
in women within Europe between 2009 and 
2010. Of these ~12% were in women under 
50 years old. Although, progress in cancer 
therapies has improved the long-term 
survival of many cancer patients, aggressive 
cytotoxic therapy, which includes 
chemotherapy and/or radiotherapy, whilst 
curative, may cause premature ovarian 
failure (POF). For women of this particular 
age group premature ovarian failure and 
infertility is one of the most common 
adverse effects (10).  
At diagnosis, these patients may be 
presented with the option of having an 
emergency cycle of ovarian stimulation 
followed by oocyte or embryo freezing to 
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allow assisted conception after successful 
cancer treatment. However, this option 
invariably delays cancer therapy. 
Furthermore is not an appropriate method 
for pre-pubescent patients or those with 
hormone-sensitive tumours as they are 
unable to have any hormonal stimulation 
required for oocyte retrieval (13). 
A further problem is that oocyte 
freezing has low rates of success as the cell 
has relatively high water content and as such 
is particularly prone to cryoinjury. Embryo 
freezing is much more successful and is an 
established technique. However if the 
patient does not have a conception partner at 
diagnosis then she must accept the use of 
donor sperm to create embryos in order to 
improve her chances of successful 
conception at a later date. 
As there is no way to predict ovarian 
failure induced by chemo/radiotherapy, 
cryopreservation of the ovarian tissue prior 
to cytotoxic treatment could be 
advantageous. By dissecting the thin layer of 
cortex from the underlying medulla, follicles 
within the ovarian tissue can be 
cryopreserved for future use. Unlike 
freezing individual oocytes or embryos, 
ovarian tissue cryopreservation facilitates a 
more efficient way of preserving thousands 
of immature follicles at one time (14). This 
not only increases the number of preserved 
oocytes, but also does not delay the start of 
therapeutic treatment, and eliminates the 
need for ovarian stimulation. Compared to 
mature oocytes, primordial follicles are 
more resistant to cryoinjury, probably 
because of their smaller size, slower 
metabolic rates and absence of the zona 
pellucid (23).  
It has been nearly 60 years since 
Parrott’s work on successful 
cryopreservation of mouse ovarian grafts 
using glycerol and slow cooling was 
published (20). In 1993, Carroll and Gosden 
(3) showed that mouse primordial follicles 
had the ability to remain fertile following 
enzymatic isolation, cryopreservation, 
storage at -196˚C in liquid nitrogen and 
retransplantation; using dimethylsulphoxide 
(DMSO) as a cryoprotective agent. Gosden 
et al (11) further explored this field with 
additional experiments, which have become 
extremely important in this area of research. 
His group reported the restoration of 
oestrous cycles and fertility to 
oophorectomised sheep following ovarian 
tissue cryopreservation, thawing and 
subsequent autografting to the ovarian bursa. 
Sheep were chosen for their ovaries likeness 
to humans in terms of size and tissue 
structure. 
These experimental models laid the 
foundations for the first attempts at human 
pregnancies achieved using ovarian tissue 
cryopreservation and transplantation in 
cancer patients. In 2004 healthy live births 
from frozen–thawed human ovarian tissue 
were claimed in lymphoma survivors who 
underwent orthotopic transplantation (8).   In 
2005, Meirow and his colleagues harvested 
ovarian tissue from a patient prior to 
undergoing high-dose chemotherapy for 
Hodgkin's lymphoma (16, 17). Thawed 
ovarian tissue was transplanted 
orthotopically, and the patient conceived 
following the transfer of a four-cell embryo 
using in vitro fertilization. This success of 
this pregnancy demonstrated that ovarian 
tissue cryopreservation and transplantation 
could not only aid in achieving conception 
but provide hormonal support which also 
may have been lost during cytotoxic 
treatment.  
However, in 2008 meta-analysis 
identified that although the technique was 
having some success it was limited. In 46 
women who underwent ovarian 
cryopreservation and transplantation, 
resumption of ovarian function was 
established with a median time of 120 days. 
Among them, four women had recurrent 
ovarian failure within 6 months. In 25 
women who sought pregnancy, eight women 
had nine pregnancies at 12 months, giving a 
cumulative pregnancy rate of 37% (1). Most 
recently worldwide, the number of live 
births as a result of frozen ovarian tissue 
transplantation had risen to 60 of which two 
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were born using vitrification as a technique 
for cryopreservation (7).  
Thus while the results for ovarian tissue 
cryopreservation are promising, the 
technique remains experimental with 
relatively low numbers of live births in 
comparison to number of transplantations 
occurring. There are many factors likely to 
be responsible for the relatively low success 
rates with this technique, both 
experimentally in terms of tissue 
conservation post-thaw and clinically in 
terms of live birth rate as a result of 
cryopreserved ovarian tissue autografting.  
An optimal protocol for cryopreservation 
and thawing is still not widely agreed upon, 
and the viability of tissue following this 
technique warrants further investigation. In 
particular, the warming profiles for 
cryopreserved ovarian tissues have not been 
evaluated. Whilst rapid warming rates have 
been widely applied in cryopreservation (9), 
early studies on embryo cryopreservation 
suggested that slow warming was effective 
(25).  More recently Seki & Mazur (2010) 
demonstrated the dominance of the impact 
of warming rate in cryopreservation of 
oocytes. However, this freezing was done 
using vitrification, which does differ greatly 
to the tissue slow cooling used in this 
research study (22).   
The aim of this study was therefore to 
investigate different warming profiles for 
cryopreserved human ovarian tissues. In 
addition, the application of a Stirling motor 
cryo-cooler for controlled slow cooling of 
human ovarian tissue was investigated.  This 
technology is electrically powered and 
negates the need for any cryogen such as 
liquid nitrogen during cryopreservation 
(Asymptote Ltd, Cambridge UK). Stirling 
motors operate by cyclic compression and 
expansion of a gas at different temperatures, 
converting heat energy to work.  However, 
this system can operate in reverse; by adding 
work in, cooling to low temperatures can be 
achieved.  This equipment has already been 
shown to be effective for cryopreservation 
of suspensions of stem cells, sperm, 
embryos and hepatocytes (1, 7, 9) and 
potentially has wider applications in 
controlled atmosphere environments such as 
operating theatres where ovarian tissues may 
be accessed.  
MATERIALS AND METHODS 
Permissions and ethical approval for 
research access to human ovarian tissues 
Ethical approval for this study was 
granted by the Fulham Research Ethics 
Committee on 16th May 2012. Reference 
Number 12/LO/0418. Furthermore, the 
Research and Development Department of 
the Royal Free Hospital allowed the study to 
be carried out on NHS premises on 1st July 
2012, reference number 8559.  
Subject group and consent  
The tissue biopsies for this particular 
study were taken from 11 women 
undergoing elective caesarean section at the 
Royal Free Hospital. Recruiting patients 
from a cohort scheduled to undergo cesarean 
section had been carried out in other studies 
investigating ovarian tissue in Leeds, UK  
Stockholm, Sweden (4, 12).  
The women selected were aged between 
18 and 35, showing no signs of 
coagulopathy or malignancy, and having the 
capability to consent. Women that fulfilled 
these criteria were identified by the 
midwifery staff when they attended the Day 
Assessment Unit two days prior to their 
operation date. At this point, the research 
teams were given an opportunity to inform 
and counsel the women regarding 
participation in the study. On the day of 
their operation, these ladies were once more 
counseled, and informed consent was 
obtained. 
Ovarian tissue collection  
Two cortical biopsies from each woman 
were taken during the caesarean section 
following closure and hemostasis of the 
uterine incision, in order to prevent any 
excessive blood loss. The biopsies were 
taken using a 6 mm diameter Stiefel Punch 
Biopsy tool, which separated the required 
tissue from the loose medullary tissue 
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underneath. This all ensured uniform size of 
the biopsy.  
The tissue biopsies were immediately 
placed into Leibovitz-L15 medium (Life 
Technologies, Invitrogen Ltd, Paisley, UK) 
supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS) (Life 
Technologies, Invitrogen Ltd, Paisley, UK) 
and 0.1 mol L-1 sucrose solution (Sigma-
Aldrich company Ltd, Gillingham, Dorset, 
UK) at 4°C and subsequently transported to 
the laboratory on ice, where the two 
cylindrical biopsies were cut in half using a 
scalpel, leaving four separate tissue pieces. 
Three pieces from each patient were 
cryopreserved for the research study and 
where possible one piece was processed 
fresh to act as control. Given certain 
logistical constraints it was not always 
feasible to conduct an assay on fresh tissue. 
Ovarian tissue freezing  
Cryopreservation and rewarming of all 
ovarian tissues was performed in the Cell, 
Tissue and Organ Cryopreservation Unit of 
Molecular Biology Laboratory, UCL. Each 
patient’s sample was processed and 
cryopreserved when received.  
Freezing solution consisted of Leibovitz 
L-15 medium supplemented with 1.5 mol L-1 
DMSO (Sigma-Aldrich company Ltd, 
Gillingham, Dorset UK) as cryoprotectant 
(CPA), 10% (v/v) FBS and 0.1 mol L-1 
sucrose, which was prepared and stored at 
4°C. Each cryovial (Corning B.V. Life 
Science, Amsterdam, Netherlands) was 
preloaded with IceStart autonucleation beads 
(Asymptote, Cambridge, UK). One ml of the 
freezing solution was added to each cryovial 
and they were stored at 4°C. Each ovarian 
fragment was transferred into one cryovial 
and held at 4°C for 10 min for CPA 
permeation. The Asymptote EF600 
controlled rate freezer (Asymptote, 
Cambridge, UK) was used to perform the 
freezing protocol. The freezing protocol was 
performed at the following cooling rates: 
from 4°C to -7°C at 2°C min-1, maintained at 
-7°C for 10 min for seeding, then cooling to 
- 40°C at 0.3°C min-1 and to -80°C with the 
rate of -5°C min-1 (18). The cryovials, were 
later plunged into liquid nitrogen at -196°C, 
and stored (for a minimum of 14 d or longer) 
until they were rewarmed for assessment 
(18). This cooling profile can be seen in 
Figure 1.  
Preparation of cortical slices and 
visualization using neutral red staining  
Fresh control tissues or those previously 
cryopreserved were sectioned using a Leica 
VT1000S microtome with vibrating blade 
(Vibratome) to produce tissue slices that 
were approximately between 80 µm and 100 
 
Plate 
temperature 
(˚C) 
Time elapsed (mins) 
 
Figure 1. Cooling profile for cryopreservation of ovarian tissue. From Newton et al (18). 
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µm thick and 1 x 1 mm in size. Not all slices 
were exactly uniform. Each ovarian biopsy 
was secured to the cutting stage with 
cyanoacrylate glue, and the stage immersed 
in a solution bath containing HEPES-
modified minimum essential medium (H-
MEM) supplemented with 0.1% (w/v) 
bovine serum albumin fraction V (BSA) and 
1% (v/v) penicillin G/streptomycin sulphate. 
The solution bath was surrounded by ice to 
maintain the sectioning solution at 0°C. 
Initial work was performed with pieces of 
animal liver and kidney tissue (purchased 
from retail outlets) as comparable tissue-
consistency models for human ovarian 
tissue. Using this model, the settings of the 
vibratome were optimised for cutting tissue 
of this consistency at 0.24 mm s-1 cutting 
speed, at a blade vibration frequency of 60 
to 70 Hz. These settings offered the best 
quality slices most rapidly. 
After slicing the human ovarian tissue 
samples, slices were placed into sterile four-
well culture plates, with each well 
containing 500 µL of serum-free culture 
medium with dissolved neutral red (NR). 
The culture medium consisted of alpha-
minimum essential medium (α-MEM) 
supplemented with Glutamax, 0.1% (w/v) 
BSA, 1% (v/v) penicillin G/streptomycin 
sulphate and 0.1mol L-1 sucrose solution. 
The NR dye was diluted in the culture 
solution to a final concentration of 50 µg 
mL-1. The four-well plates were then 
incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air for 4 h. After 
incubation, the tissue pieces were washed in 
fresh culture medium (without NR) three 
times and then observed using dark-field 
microscopy. The number of red structures in 
each tissue slice was then counted and each 
slice photographed. 
Thawing protocols  
Ovarian tissue fragments were kept 
frozen between 14 and 76 d prior to thawing 
using different protocols. One piece of tissue 
from each biopsy was thawed following the 
three protocols:   
Protocol 1 (rapid-thawing) - has been 
previously reported by Newton et al (18). 
Three DMSO wash solutions were prepared 
in stepwise dilution, containing Lebovitz L-
15 medium supplemented with DMSO in 1, 
0.5 and 0 mol L-1, 10% (v/v) FBS and 0.1 
mol L-1 sucrose stored at 4°C. The vials of 
cryopreserved ovarian biopsies were 
rewarmed in air at room temperature for 120 
s, followed by immersion in a water bath at 
37°C for a further 120 s (total time 4 min) 
until visible ice had disappeared (average 
warming rate of about +50°C min-1). 
Following thawing, the ovarian tissue was 
washed by agitating in the sequential 
dilutions of DMSO solution for 2 min in 
each solution, to remove any excess CPA.  
The tissues were then sectioned using the 
Vibratome as described above.  
Protocol 2 (ultra-fast thawing) -  has been 
previously described by Martinez-Madrid 
(15) when they cryopreserved whole 
ovaries. This is a very rapid-thawing 
protocol which consists of taking the 
cryovials out of liquid nitrogen and plunging 
immediately into a waterbath at 60°C until 
the solid phase has completely melted. This 
takes approximately 80 to 100 s (total time 
1.5 min) with an average warming rate of 
about +120oC min-1. The tissue was 
considered thawed when visible ice crystals 
had disappeared. Again, the stepwise 
dilution process was applied. After thawing, 
the tissue was washed in Leibovitz-L15 
medium supplemented with 10% (v/v) heat-
inactivated FBS, 0.1 mol L-1 sucrose 
solution and decreasing concentrations of 
DMSO (1 M, 0.5 M, 0 M) to expel the 
cryoprotective agent from the tissue and 
culture medium. The tissue was then 
sectioned in the manner described above.  
Protocol 3 (slow warming) - was attempted 
by reversing the slow cooling profile on the 
Asymptote EF600. The machine was 
reprogrammed to initiate passive warming at 
a rate of approximately +1oC min-1. When 
the reserve cycle was complete, the tissues 
were considered to be thawed.  
 
Statistical analysis  
Data evaluation was carried out using 
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Statistical Package for the Social Sciences 
(SPSS) (IBM SPSS Statistic 21, IBM 
Corporation, Armonk, NY, USA). A P value 
< 0.05 was considered statistically 
significant. The comparisons between fresh 
and cryopreserved xenotransplanted tissue 
were carried out using a Wilcoxon’s signed 
ranks test, a non- parametric test used to 
compare our matched samples.  
RESULTS 
Follicle counts and neutral red staining of 
cortical ovarian tissue slices 
A total of 164 cryopreserved and fresh 
slices were analysed from the biopsies. 
There were no fresh comparison biopsies in 
five cases, which were due to logistical 
reasons with the assay.  In these instances, 
all four pieces of the tissue biopsy were 
cryopreserved. 
The mean number of NR follicles per 
slice was highest for the fresh tissue (7.6 per 
slice, n=6) as expected, but there was 
reasonable conservation of follicles in the 
cryopreserved group thawed using Protocol 
1 with a mean follicle count of 4.0 (n=11). 
Protocol 2 resulted in larger follicle losses 
with a mean follicle count of 1.9 per slice 
following this thawing protocol (n=11). 
Contrastingly, Protocol 3 showed an 
extremely low conservation rate with a mean 
attrition rate of 98.85%. The staining of 
these follicles is questionable as very few of 
the NR follicles out of a total of all follicles 
present expressed the red colour. As such 
the data for this protocol is not included in 
Table 1.   
Using Wilcoxon’s signed ranks test the 
data show a significant decrease in mean 
follicle count between fresh tissue and 
cryopreserved tissue thawed using Protocol 
1 and that thawed using Protocol 2 (p<0.05, 
n=6.) When the mean follicle counts in 
tissue thawed by the two protocols are 
compared, the difference is highly 
significant with Protocol 2 being the less 
successful (p<0.01, n=11).  
 
Follicle conservation rates 
The data in Table 1 shows that there is a 
greater mean follicle conservation rate in 
tissue thawed with Protocol 1 (27%) 
compared to that thawed with Protocol 2 
(13%). These percentages were calculated 
by comparison with paired counts in the 
fresh tissues when these were available. The 
fresh biopsies were sliced at the time of 
collection, whilst the cryopresrevd biopsies 
were sliced after thawing.  Of the cortical 
slices obtained, 97.1% of the fresh slices 
stained positive for neutral red in follicles. 
In some experiments fresh counts were not 
possible because of small size of the initial 
biopsies.  Overall follicle conservation was 
found in 112 out of 164 tissue slices from 
cryopreserved tissue (68.3%). A visual 
example of NR positive follicles in a fresh 
tissue slice is shown in Figure 2.    
Table 1. Mean follicle conservation rates 
in tissue thawed using the two protocols.  
Thawing 
protocol 
Mean follicle 
conservation 
(%) 
Mean follicle 
attrition (%) 
1 27 73 
2 13 87 
 
 
 
Figure 2: Follicles stained with NR in situ in 
fresh cortical ovarian slices. 
143 
 
DISCUSSION 
The potential for human ovarian tissue 
cryopreservation as a method of fertility 
preservation in young women about to 
embark on treatment for malignancy, is 
highly significant in light of recent 
improvements in cancer survival rates (5). 
Cytotoxic treatments cause depletion to the 
ovarian follicle reserve rendering patients 
sterile or inducing early menopause (2, 24). 
For those women who may still wish to 
conceive, restoring their reproductive 
capabilities after treatment is often one of 
their greatest concerns.  
Our experiments indicate that ovarian 
tissue cryopreservation and transplantation 
is a successful technique, with numbers of 
follicles identified in the majority of tissue 
slices prepared from the biopsies. The NR 
staining test has been applied to ovarian 
slices before (4, 6) and relies on uptake of 
stain and accumulation within lysozomes by 
viable follicles, with non-viable follicles 
showing absence of staining (4). 
Additionally, we have utilised an 
experimental protocol for the in-situ 
identification of viable follicles, which has 
been used only once previously, and have 
demonstrated follicle-staining rates 
comparable to those obtained by the original 
authors (4). 
The presence of follicles in the tissue 
stained by the NR dye correlated to the 
predicted number of follicles found in the 
histological data, thereby validating NR as a 
legitimate method to detect viable follicles 
within slices of ovarian tissue (4).   
The Stirling motor cryo-cooler used in 
the cryopreservation work (EF600) 
functioned well with the slow cooling 
profiles applied for ovarian tissues. There 
have been a number of studies using these 
profiles, with similar slow cooling rates 
(19). For human tissues, the majority of live 
births have resulted from slow cooling 
cryopreservation (21). Whilst vitrification as 
a technique for ovarian tissue cryo-banking 
has been more recently studied in some 
animal models, few human live births have 
been reported. The ability to use the 
electrically powered Stirling motor cryo-
coolers may be more convenient in 
operating theatre suites where biopsies are 
being harvested, thereby possibly improving 
the logistics of cryopreservation.  
The importance of warming profiles has 
not often been studied in human ovarian 
tissue cryopreservation and very little is 
published on the topic. The data provided 
here suggests that moderately fast warming 
rates (Protocol 1) resulted in higher 
maintenance of viable follicles compared to 
ultra-fast rates (Protocol 2), where warming 
rates were calculated according to the 
shortest time taken for all ice crystals to 
disappear.  
Rapid warming in general has become 
accepted as beneficial to avoid prolonged 
exposure of the tissues to high salt and CPA 
concentrations as the ice matrix melts, whilst 
minimizing the potential for any ice nuclei 
to rearrange into intracellular ice. However, 
there is also the concern that differential 
thermal profiles caused across tissues during 
fast warming by the thermal – mechanical 
properties of the materials at very low 
temperatures may cause stress and cracking 
events (21), which can also be injurious. 
This may be one reason why the ultra-fast 
Protocol 2 was less successful.        
In summary this study shows that 
thawing conditions significantly affect 
follicle conservation in cryopreserved 
human ovarian tissue and there is a great 
need for an optimized protocol to ensure 
conservation of follicles.  
Acknowledgements: This work was funded 
by the Betty Austin Memorial Entry-Level 
Scholarship, Wellbeing of Woman.  
REFERENCES 
1. Bedaiwy MA, El-Nashar SA, El Saman 
AM, Evers JL, Sandadi S, Desai N, & 
Falcone T (2008) Human Reprod. 23, 
2709–2717. 
2. Cancer Research UK, 2016 
http://www.cancerresearchuk.org/health-
144 
 
professional/cancer-statistics (accessed 
November 2016). 
3. Carroll J & Gosden RG (1993) Human 
Reprod. 8, 1163-1167.  
4. Chambers EL, Gosden RG, Yap C &  
Picton HM (2010) Human Reprod. 25, 
2559–2568.  
5. Donnez J & Dolmans M-M (2013) 
Nature Reviews. Endocrinology 9, 735–
49. 
6. Donnez J & Dolmans MM (2015)  
Current Opinion Obstet Gynecol. 27, 
222-30. 
7. Donnez J & Dolmans MM (2015) J. 
Assist. Reprod. Genet. 32, 1167–1170. 
8. Donnez J, Dolmans MM, Demylle D, 
Jadoul P, Pirard C, Squifflet J, Martinez-
Madrid B & van Langendonckt A (2004)  
Lancet 364, 1405–1410.  
9. Fleck R & Fuller B (2007) In Medicines 
from Animal Cell Culture, eds G Stacey & 
J Davis. John Wiley Press, UK. pp 417-
431. 
10. Gook DA, Osborn SM, Archer J, Edgar 
DH & McBain J (2004) Eur. J. Obstet. 
Gynecol. Reprod. Biol. 13 (Suppl 1), 
S60–62. 
11. Gosden RG, Baird DT, Wade JC & 
Webb R (1994) Human Reprod. 9, 597–
603. 
12. Hreinsson J, Zhang P, Swahn ML, 
Hultenby K & Hovatta O (2003)  Human 
Reprod. 18, 2420–2428. 
13. Jorssen EPA, et al. (2015)  
Theriogenology 84, 301-311. 
14. Kondapalli LA (2012) In Oncofertility 
Medical Practice: Clinical Issues and 
Implementation, (eds) C Garcia & TK 
Woodruff.   Springer Science+Business 
Media, New York. Pp 63-75.  
15. Martinez-Madrid B, Camboni A, 
Dolmans MM, Nottola S, Van 
Langendonckt A & Donnez J (2007) 
Fertil. Steril. 87, 1153-1165. 
16. Meirow D & Nugent D (2001). Human 
Reprod. Update 7, 535–543.  
17. Meirow D, Levron J, Eldar-Geva T, et al 
(2005) New England J. Med. 353, 318-
321. 
18. Newton H, Picton H, Gosden RG (1999) 
J. Reprod. Fertil. 15, 141–150.  
19. Oktay K, Nugent D, Newton H, Salha O, 
Chatterjee P & Gosden RG (1997) . 
Fertil. Steril. 67, 481–486.  
20. Parrott DMV (1960) J. Reprod. Fertility 
1, 230-241. 
21. Rabin Steif PS, Palastro M, Wan CR, 
Baicu S, Taylor MJ & Rabin Y (2005)  
Cell Preserv. Technol. 3, 184-200. 
22. Seki S & Mazur P (2010) Cryobiology 
61, 155-7. 
23. Seli E & Tangir J (2005) Current 
Opinion Obstet. Gynecol. 17, 299–308.  
24. Wallace WHB, Anderson RA & Irvine 
DS (2005) Lancet Oncol. 6, 209–218. 
25. Whittingham DG, Leibo SP  & Mazur P 
(1972) Science 178, 411-4. 
 
 
 
 
 
